Combinations of QTc-prolonging drugs

• Verfasst von: Meid, Andreas [VerfasserIn]
• Verfasst von: Mächler, Sarah [VerfasserIn]
• Verfasst von: Mikus, Gerd [VerfasserIn]
• Verfasst von: Haefeli, Walter E. [VerfasserIn]
• Titel: Combinations of QTc-prolonging drugs
• Titelzusatz: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature
• Verf.angabe: Andreas D. Meid, Irene Bighelli, Sarah Mächler, Gerd Mikus, Giuseppe Carrà, Mariasole Castellazzi, Claudio Lucii, Giovanni Martinotti, Michela Nosè, Giovanni Ostuzzi, Corrado Barbui and Walter E. Haefeli
• E-Jahr: 2017
• Jahr: August 28, 2017
• Umfang: 14 S.
• Teil: volume:7
• Teil: year:2017
• Teil: number:12
• Teil: pages:251-264
• Teil: extent:14
• Fussnoten: Article first published online: August 28, 2017 ; Gesehen am 24.09.2018
• Titel Quelle: Enthalten in: Therapeutic advances in psychopharmacology
• Ort Quelle: London [u.a.] : Sage Publ., 2011
• Jahr Quelle: 2017
• Band/Heft Quelle: 7(2017), 12, Seite 251-264
• ISSN Quelle: 2045-1261
• DOI: doi:10.1177/2045125317721662
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1581231016

Abstract

Background: Whether arrhythmia risks will increase if drugs with electrocardiographic (ECG) QT-prolonging properties are combined is generally supposed but not well studied. Based on available evidence, the Arizona Center for Education and Research on Therapeutics (AZCERT) classification defines the risk of QT prolongation for exposure to single drugs. We aimed to investigate how combining AZCERT drug categories impacts QT duration and how relative drug exposure affects the extent of pharmacodynamic drug?drug interactions.Methods:In a cohort of 2558 psychiatric inpatients and outpatients, we modeled whether AZCERT class and number of coprescribed QT-prolonging drugs correlates with observed rate-corrected QT duration (QTc) while also considering age, sex, inpatient status, and other QTc-prolonging risk factors. We concurrently considered administered drug doses and pharmacokinetic interactions modulating drug clearance to calculate individual weights of relative exposure with AZCERT drugs. Because QTc duration is concentration-dependent, we estimated individual drug exposure with these drugs and included this information as weights in weighted regression analyses.Results:Drugs attributing a ?known? risk for clinical consequences were associated with the largest QTc prolongations. However, the presence of at least two versus one QTc-prolonging drug yielded nonsignificant prolongations [exposure-weighted parameter estimates with 95% confidence intervals for ?known? risk drugs + 0.93 ms (?8.88;10.75)]. Estimates for the ?conditional? risk class increased upon refinement with relative drug exposure and co-administration of a ?known? risk drug as a further risk factor.Conclusions:These observations indicate that indiscriminate combinations of QTc-prolonging drugs do not necessarily result in additive QTc prolongation and suggest that QT prolongation caused by drug combinations strongly depends on the nature of the combination partners and individual drug exposure. Concurrently, it stresses the value of the AZCERT classification also for the risk prediction of combination therapies with QT-prolonging drugs.